Ms. Anchisa Lekpetch, Chief Accounting and Finance Officer, and Dr. Wasawat Sroithong, Investor Relations Officer of Medeze Group Public Company Limited (SET: MEDEZE), jointly presented the company’s 2Q26 results at the Opportunity Day event organized by The Stock Exchange of Thailand.
For the second quarter of 2026, the company reported a net profit of THB 40.18 million, an increase of THB 5.81 million or approximately 17% from the previous quarter’s net profit of THB 34.37 million. Total revenue for the quarter was THB 170.31 million. The company’s net profit has shown a strong recovery over the past four quarters, rising from THB 30.54 million, THB 36.43 million, and THB 34.37 million in 3Q25, 4Q25, and 1Q26, respectively.
MEDEZE continues to build on its business success, becoming the very first and only entity in Thailand to achieve the cell bank standard, together with certifications for type 2 drug manufacturing license, AABB, and ISO, as well as participating in the ATMPs Regulatory Sandbox. These milestones drive innovation in stem cell and advanced medical products within Thailand.
Previously, MEDEZE has elevated its medical infrastructure following attainment of the cell bank standard, targeting GMP certification by 4Q26 and beginning clinical trials for osteoarthritis treatment and skin rejuvenation in 2027. Commercial production of cell culture media is planned for 2028, aiming to reduce imports, while expanding into the Philippine market—further solidifying MEDEZE’s leadership in medical innovation both domestically and abroad.
